SCHEMBL277729

SCHEMBL277729

Oc1ccn2ccccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 2/20 0.40
KDM4E B2RXH2 6/20 0.36
RAB9A P51151 5/20 0.36
ALDH1A1 P00352 4/20 0.36
NPC1 O15118 3/20 0.36
HPGD P15428 3/20 0.36
MAPT P10636 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HSD17B10 Q99714 2/20 0.36
CA12 O43570 1/20 0.36
GMNN O75496 1/20 0.36
EGFR P00533 1/20 0.36
CA2 P00918 1/20 0.36
LMNA P02545 1/20 0.36
FYN P06241 1/20 0.36
POLB P06746 1/20 0.36
CA3 P07451 1/20 0.36
CYP3A4 P08684 1/20 0.36
MMP9 P14780 1/20 0.36
NFKB1 P19838 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Biphenyl SCHEMBL7408683 0.91 BCL2L1 (0.39) ALOX15KDM4ERAB9AALDH1A1NPC1
SCHEMBL276894 0.84 ALDH1A1 (0.40) ALOX15KDM4ERAB9AALDH1A1NPC1
SCHEMBL31609391 0.74 ALOX15 (0.43) ALOX15KDM4ERAB9AALDH1A1NPC1
SCHEMBL5356722 0.70 ALOX15 (0.40) ALOX15KDM4ERAB9AALDH1A1HPGD
SCHEMBL2005730 0.70 ALOX15 (0.40) ALOX15KDM4EALDH1A1HPGDGAA
SCHEMBL28564397 0.70 ALOX15 (0.40) ALOX15KDM4ERAB9AALDH1A1NPC1
SCHEMBL16915952 0.70 ALOX15 (0.40) ALOX15KDM4ERAB9AALDH1A1NPC1
SCHEMBL2005732 0.70 ALOX15 (0.40) ALOX15KDM4ERAB9AALDH1A1NPC1
SCHEMBL4397520 0.70 KDM4E (0.41) ALOX15KDM4ERAB9AALDH1A1NPC1
SCHEMBL28372316 0.70 ALOX15 (0.40) ALOX15KDM4ERAB9AALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104144930-A New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same SERVIER LAB 2014-11-12 CN claimed
CN-1105030-C Thermal waterless lithographic printing plate KODAK POLYCHROME GRAPHICS CO (US) 2003-04-09 CN claimed
CN-1269752-A Thermal waterless lithographic printing plate KODAK POLYCHROME GRAPHICS CO (US) 2000-10-11 CN claimed
US-12605449-B2 Drug-clay mineral complex containing phospholipid and oral administration composition including same KOREA INSTITUTE OF GEOSCIENCE AND MINERAL RESOURCES (KR) 2026-04-21 US disclosed
US-12458702-B2 Conjugate for targeting therapy NATIONAL TAIWAN UNIVERSITY (TW) 2025-11-04 US disclosed
US-12419964-B2 Antibody drug conjugate (ADC) targeting Nectin 4 and comprising an exatecan payload ELI LILLY AND COMPANY (US) 2025-09-23 US disclosed
US-20250127916-A1 ANTIBODY DRUG CONJUGATE (ADC) TARGETING NECTIN 4 AND COMPRISING AN EXATECAN PAYLOAD ELI LILLY AND COMPANY 2025-04-24 US disclosed
US-20240158410-A1 CAMPTOTHECIN COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2024-05-16 US disclosed
CN-117835980-A Tetrahydropyrazolopyridine analog ligand of NLRX1 and application thereof 朗多生物制药股份有限公司 2024-04-05 CN disclosed
US-20230310618-A1 CONJUGATE FOR TARGETING THERAPY NATIONAL TAIWAN UNIVERSITY (TW) 2023-10-05 US disclosed
EP-4214200-A1 LANCL LIGANDS Nimmune Biopharma, Inc. (US) 2023-07-26 EP disclosed
CN-1452731-A On-press development of heat sensitive lithographic plates TENG GARY GANGHUI (US) 2003-10-29 CN disclosed
CN-1425141-A Laser-induced thermal transfer recording process DU PONT (US) 2003-06-18 CN disclosed
CN-1105030-C Thermal waterless lithographic printing plate KODAK POLYCHROME GRAPHICS CO (US) 2003-04-09 CN disclosed
CN-1269752-A Thermal waterless lithographic printing plate KODAK POLYCHROME GRAPHICS CO (US) 2000-10-11 CN disclosed
US-5674879-A Compositions including and methods of using conformationally restricted angiotensin II antagonist G.D. SEARLE & CO. (US) 1997-10-07 US disclosed
EP-0483851-B1 Pyrazolyl acrylic acid derivatives, intermediates thereto, and agricultural/horticultural fungicides containing said derivatives MITSUBISHI CHEM CORP (JP) 1996-03-13 EP disclosed
US-5426105-A Cardiovascular disorders G.D. SEARLE & CO. (US) 1995-06-20 US disclosed
US-5128350-A PYRAZOLYL ACRYLIC ACID DERIVATIVES AND AGRICULTURAL/HORTICULTURAL FUNGICIDES CONTAINING SAID DERIVATIVES MITSUBISHI KASEI CORPORATION (JP) 1992-07-07 US disclosed
EP-0483851-A1 Pyrazolyl acrylic acid derivatives, intermediates thereto, and agricultural/horticultural fungicides containing said derivatives Mitsubishi Chemical Corporation (JP) 1992-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158410-A1 CAMPTOTHECIN COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF WEE1, WEE2, PCLAF ALOX15 468/4885KDM4E 4411/4885RAB9A 1971/4885
US-12419964-B2 Antibody drug conjugate (ADC) targeting Nectin 4 and comprising an exatecan payload NECTIN4, SDC4, EPCAM ALOX15 4815/4885KDM4E 902/4885RAB9A 628/4885
US-12605449-B2 Drug-clay mineral complex containing phospholipid and oral administration composition including same TOP1, ABCB11, PCTP ALOX15 3102/4885KDM4E 749/4885RAB9A 1570/4885
US-12458702-B2 Conjugate for targeting therapy FOLH1, CD44, SLC10A1 ALOX15 3580/4885KDM4E 3131/4885RAB9A 425/4885
US-20250127916-A1 ANTIBODY DRUG CONJUGATE (ADC) TARGETING NECTIN 4 AND COMPRISING AN EXATECAN PAYLOAD NECTIN4, SDC4, EPCAM ALOX15 4815/4885KDM4E 902/4885RAB9A 628/4885
US-20230310618-A1 CONJUGATE FOR TARGETING THERAPY FOLH1, CD44, SLC10A1 ALOX15 3580/4885KDM4E 3131/4885RAB9A 425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.